Patents Examined by J. Hines
  • Patent number: 8822211
    Abstract: The invention concerns a device and a method for concentrating pathogenic germs potentially present in blood products or derivatives and for detecting said germs comprising the following steps: (a) subjecting a sample of said blood product to a blood cell aggregating treatment, (b) eliminating the aggregates formed at step (a) by passing the treated sample over a first filter allowing through the contaminating germs but not the cell aggregates, (c) selectively lyzing the residual cells of the filtrate obtained at step (b), (d) recuperating the contaminating germs by passing the lysate of step (c) over a second filter to detect the contaminating germs possibly trapped.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: September 2, 2014
    Assignee: Becton Dickinson Infusion Therapy Systems Inc.
    Inventors: Jean-Pierre Hermet, Isabelle Besson-Faure, Sebastien Ribault, Yann Godfrin, Anne Monnot des Angles
  • Patent number: 8642283
    Abstract: The present invention provides an assay for the identification of agents which can modulate TOR-mediated phosphorylation of substrate proteins. The assays of the invention utilize substrate proteins whose amino acid sequence contains the Ser/Thr motif recognized by TOR. Naturally occurring TOR which may be used in the methods of the invention include TOR isolated from a variety of species, particularly mammalian tissues.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: February 4, 2014
    Assignee: Sanford-Burnham Medical Research Institute
    Inventor: Robert T. Abraham
  • Patent number: 8586349
    Abstract: The present invention concerns a method for the detection of an analyte in a droplet of fluid comprising the steps of providing a solid phase with a hydrophobic surface comprising at least one capture zone on which at least one binding agent with affinity for the analyte is immobilized, applying said droplet to the surface of said solid phase, applying a force that makes the droplet travel along the surface of said solid phase along a predetermined path thereby allowing the droplet to repeatedly contact said binding agent on the capture zone, applying conditions wherein said analyte is allowed to bind to said binding agent and detecting a complex of analyte and binding reagent at the position of the capture zone. The effect of a moving droplet is that the reactants in the droplet are well mixed which eliminates the risk of diffusion limitation. Such advantageous mixing is not obtained with conventional assays in which the surface is continuously exposed to the liquid.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: November 19, 2013
    Assignee: Biomerieux B.V.
    Inventors: Thomas Augustinus Maria Beumer, Petrus Franciscus Hendrikus M. Verheijden, Hendrik Sibolt van Damme
  • Patent number: 8481054
    Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?3) ribitol (5?phosphate}. This new serotype may be included in pneumococcal vaccines.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: July 9, 2013
    Assignees: The UAB Foundation, Fundacao Oswald Cruz, Instituto Adolfo Lutz
    Inventors: Moon H. Nahm, Jisheng Lin, Angela P. Brandao, Maria Cristina Brandileone
  • Patent number: 8409563
    Abstract: A purine-derived substance is produced by culturing a bacterium belonging to the genus Bacillus which is able to produce purine-derived substance and has been modified so that enzymatic activity of fructose bisphosphatase is decreased, and collecting the purine-derived substance from the medium or cells.
    Type: Grant
    Filed: October 21, 2008
    Date of Patent: April 2, 2013
    Assignee: Ajinomoto Co., Inc.
    Inventors: Takayuki Asahara, Kiyoshi Matsuno, Yukiko Mori
  • Patent number: 8343726
    Abstract: The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: January 1, 2013
    Assignee: Techlab, Inc.
    Inventors: James H. Boone, David M. Lyerly, Tracy D. Wilkins
  • Patent number: 7993917
    Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: August 9, 2011
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: Samuel K. Martin
  • Patent number: 7887817
    Abstract: A process for preventing a protozoal disease by the administration of an alkyl phosphocholine to a human being.
    Type: Grant
    Filed: January 8, 2003
    Date of Patent: February 15, 2011
    Assignee: AEterna Zentaris GmbH
    Inventor: Jürgen Engel
  • Patent number: 7776332
    Abstract: A composition for an infant formula which includes casein protein and whey protein; a method of producing the composition; use of the composition in the manufacture of a medicament or nutritional product for addressing malnutrition; and a method of addressing malnutrition which includes administering an effective amount of the composition are provided. The composition includes protein, free arginine; tryptophan and histidine, a lipid source and a carbohydrate source. In addition, the whey protein is sweet whey protein from which caseino-glyco-macropeptide has been removed.
    Type: Grant
    Filed: September 12, 2000
    Date of Patent: August 17, 2010
    Assignee: Nestec S.A.
    Inventors: Martinas Kuslys, Marie-Christine Secretin, Rolf Jost, Jean-Claude Maire, Olivier Ballevre, Ferdinand Haschke, Zdenek Kratky, Niklaus Meister
  • Patent number: 7771972
    Abstract: The present invention relates to the cloning, sequencing and analysing of a gene cluster encoding a modular polyketide synthase enzyme involved in the biosynthesis of the antitumor compound pederin. This novel cluster represents the first example of genes from an unculturable symbiont encoding the biosynthesis of a drug candidate.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: August 10, 2010
    Assignee: Rheinische Friedrich-Wilhelms-Universitaet Bonn
    Inventor: Jörn Piel
  • Patent number: 7687278
    Abstract: A pretreatment kit and a pretreatment kit for saliva in identification and quantitative determination of Streptococci mutans by immunochromatography utilizing an antigen-antibody reaction, which can remove aggregation caused by mucin and chain formation of Streptococci mutans in saliva in a simple operation and can efficiently flow out a complex of a labeled antibody and Streptococci mutans from a porous membrane retaining the labeled antibody, contains (A) a 0.01 to 10 mol/L aqueous solution of sodium hydroxide, (B) a 0.01 to 3 mol/L aqueous solution of tartaric acid and/or citric acid, and (C) a nonionic surface active agent and/or an amphoteric surface active agent, in which the component (C) is mixed with the components (A) and/or (B), or is provided separately, and at least one substance selected from the particular metallic salts is contained in at least one of the components (A), (B) and (C) in an amount of 5 to 25% by weight.
    Type: Grant
    Filed: April 13, 2006
    Date of Patent: March 30, 2010
    Assignee: GC Corporation
    Inventor: Atsushi Tachino
  • Patent number: 7547536
    Abstract: A method of detecting the presence and quantity of bacterial spores, which includes adding an electrophilic alcohol and an acid anhydride to a sample, admixing the sample with a solvent, and analyzing the sample. The sample may be analyzed by injecting the mixture into a gas chromatograph equipped with a mass spectra detector.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: June 16, 2009
    Assignee: JEOL USA, Inc.
    Inventors: James A. Laramée, Robert B. Cody
  • Patent number: 7521187
    Abstract: This invention relates generally to the freeze-drying of formulations comprising a polynucleotide, a block copolymer and a cationic surfactant. In the presence of a cryoprotectant or bulking agent, a formulation can be freeze-dried, whereby upon reconstitution of the dried formulation, the microparticles maintain their optimal size and aggregation or fusion is avoided.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: April 21, 2009
    Assignee: Vical Incorporated
    Inventor: Andrew Geall
  • Patent number: 7449340
    Abstract: The present invention relates to a method for the early diagnosis of cancer in a subject, which is based on determination of the relative fraction of microorganisms derived from the feces of the subject, as compared to the total count of microorganisms in the same of corresponding sample. This relation has been found to be indicative of the presence or absence of cancer in said subject. After isolating at least one of the microorganisms from the fecal sample to form a so-called diagnostic sample, and incubating, for a sufficient time, the diagnostic sample with cancer cells. The microorganism being in an amount corresponding to its relative fraction in the original fecal sample, the cancerolytic activity of the microorganism/s is indicative to the presence or absence of cancer cells in the subject. The cancerolytic activity is expressed by terms of a tumor cell necrosis index (TCNI).
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: November 11, 2008
    Assignee: Era-Massis, Inc.
    Inventors: Gil Tenne, Mark L. Levitt, Anahit Karapetian
  • Patent number: 7422849
    Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: September 9, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ian D. Hiles, Michael J. Fry, Ritu Dhand, Michael D. Waterfield, Peter J. Parker, Masayuki Otsu, George Panayoutou, Stefano Volinia, Ivan Gout
  • Patent number: 7374765
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: May 20, 2008
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: John N. Feder, Randall C. Schatzman, Zenta Tsuchihashi
  • Patent number: 7344849
    Abstract: The present invention relates to assay methods for the determination of cobalamin or vitamin B12 in a body fluid and in particular to assay methods for the metabolically active pool of cobalamin, comprising contacting a cell free sample of a body fluid with an immobilised or immobilizable specific binding ligand for TC II or holo TC II, separating a ligand bound fraction from a non-ligand bound fraction and measuring the holo-TC II or TC-II bound cobalamin content therein.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: March 18, 2008
    Assignee: Axis-Shield ASA
    Inventors: Erling Sundrehagen, Lars Örning
  • Patent number: 7297529
    Abstract: An embodiment of the present invention provides a method for performing a lateral flow assay. The method includes depositing a sample on a test strip at an application region, detecting a first detection signal arising from the test strip in the first detection zone, and generating a baseline for the first measurement zone by interpolating between values of the detection signal outside of the first measurement zone and inside of the first detection zone. The method may include locating a beginning boundary and an ending boundary for the first measurement zone on the test strip. Additional detection zones having measurement zones may also be incorporated with the embodiment.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: November 20, 2007
    Assignee: Relia Diagnostic Systems, LLC
    Inventors: Alan J. Polito, Richard M. Thayer, Robert K. DiNello, George H. Sierra, Dennis Nixon, Alan Phillips, Stuart Neubarth
  • Patent number: 7297551
    Abstract: Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 ?M, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 ?M of SSCrFCES inhibits the LPS-induced secretion of hTNF-? and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: November 20, 2007
    Assignee: National University of Singapore
    Inventors: Jeak L. Ding, BoW Ho, Nguan S. Tan
  • Patent number: 7214788
    Abstract: Novel insect inhibitory proteins are disclosed comprising two different components, both of which are required for biological activity. Various methods of linking both components together, so that a single protein provides insect inhibitory activity, are disclosed. Also disclosed are novel Bacillus thuringiensis nucleic acid sequences encoding Coleopteran-inhibitory crystal proteins, designated tIC100 (29-kDa) and tIC101 (14-kDa). Also disclosed are methods of making and using nucleic acid sequences in the development of the transgenic plant cells containing the novel nucleic acid sequences disclosed herein.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: May 8, 2007
    Assignee: Monsanto Technology LLC
    Inventors: Victor M. Guzov, Thomas M. Malvar, James K. Roberts, Sakuntala Sivasupramaniam